Nomura Holdings
STLN

Nomura Holdings’s Starling Oncology STLN Stock Holding History

Nomura Holdings’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-33,500
Closed -$332K – 2470
2021
Q3 		$332K Hold
33,500
– – ﹤0.01% 1553
2021
Q2 		$333K Buy
+33,500
New +$337K ﹤0.01% 1552

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Nomura Holdings's STLN Position: Q4 2021 in Review

Nomura Holdings sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 33,500 shares — an estimated $332K sold.

Nomura Holdings first reported a position in STLN in Q2 2021 and held it in 2 quarters. The position peaked at $333K in Q2 2021. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • Nomura Holdings reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
  • Nomura Holdings sold 33,500 Starling Oncology shares in Q4 2021, an estimated $332K.
  • Nomura Holdings first reported a position in Starling Oncology in Q2 2021 and held it in 2 quarters.
  • Nomura Holdings's Starling Oncology position peaked at $333K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on Nomura Holdings's 13F filing for Q4 2021, filed 14 Feb 2022.